Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment of Pseudomonas aeruginosa
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1663542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Ziyun Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China. Hauptthemen laut MEDLINE: Fosfomycin, Pseudomonas aeruginosa, Azithromycin, Anti-Bacterial Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Fosfomycin combined with other antibiotics is often used to treat Pseudomonas aeruginosa infections. In this study, we investigated the effects of fosfomycin and azithromycin as monotherapy and combination therapy on the metabolic changes of multidrug-resistant P. aeruginosa .
Methods
Multidrug-resistant P. aeruginosa was exposed to fosfomycin, azithromycin, or their combination. Non-targeted metabolomic profiling was performed using LC–MS/MS. Differential metabolites were identified statistically using Student’s t-test, with significance defined as p < 0.05 and log 2 fold change (log 2 FC) ≥ 1 or ≤ −1.
Results
The minimum inhibitory concentration was 32/4 μg/mL for fosfomycin/azithromycin combination against the P. aeruginosa strain evaluated for metabolomic changes. Metabolomic analysis showed that the combination therapy resulted in greater disturbances affecting the abundance and content levels of metabolites of P. aeruginosa than monotherapies. The affected metabolic pathways were mainly amino acid metabolism, nucleotide metabolism, carbohydrate metabolism and lipid metabolism, among which nucleotide metabolism was most significantly disturbed. In the nucleotide metabolism, purine metabolism was affected more than pyrimidine metabolism.
Conclusion
Fosfomycin–azithromycin combination therapy exerted stronger interference on the metabolic pathways of P. aeruginosa than either drug alone, indicating more substantial metabolic alterations at the cellular level. These findings provide mechanistic insights that may help inform the potential application of combination regimens against multidrug-resistant P. aeruginosa in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
- School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
- Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao, China.
- Department of Statistics, State University of Maringá, Maringá, Paraná, Brazil.
Zitieren
APA
Zhao, Z., Diao, S., Song, M., Cao, X., Zhao, Y., Yu, M., Lv, Z., Sy, S. K. B., & Yang, H. (2025). Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment of Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1663542
Vancouver
Zhao Z, Diao S, Song M, Cao X, Zhao Y, Yu M, et al. Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment of Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1663542
BibTeX
@article{Zhao2025,
author = {Zhao, Ziyun and Diao, Shuo and Song, Meng and Cao, Xiujiao and Zhao, Yiran and Yu, Mingming and Lv, Zhihua and Sy, Sherwin K B and Yang, Hai},
title = {Metabolomics reveals the mechanisms of action of fosfomycin and azithromycin combination in the treatment of Pseudomonas aeruginosa},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1663542}
}
EUVIMED